← Back to Search

Cancer Vaccine

Uromune for Urinary Tract Infection

Phase 2

Waitlist Available

Led By J. Curtis Nickel, MD, FRCS

Research Sponsored by Queen's University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Study Summary

This trial will test a vaccine to help prevent recurrent urinary tract infections in Canadian women.

Eligible Conditions

Urinary Tract Infection

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Complete Responder

Secondary outcome measures

Responder Rate

Trial Design

1Treatment groups

Experimental Treatment

Group I: Open LabelExperimental Treatment1 Intervention

Uromune will be taken by the participant for 90 days.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Queen's UniversityLead Sponsor

364 Previous Clinical Trials

119,943 Total Patients Enrolled

J. Curtis Nickel, MD, FRCSPrincipal InvestigatorProfessor of Urology

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Uromune have FDA approval for use in the United States?

"While Phase 2 trials don't have data supporting efficacy, Uromune's safety has been studied to some degree--we've given it a score of 2."

Answered by AI

Does this trial have an age limit?

"This specific clinical trial is open to patients aged 18-75. If the patient does not fall into this age bracket, there are other options; 188 trials for those under 18 and 1001 trials for older adults."

Answered by AI

To get the most accurate results, who should be enrolled in this clinical trial?

"This study is looking for 62 participants between the ages of 18 and 75 who have relapsed. In addition to meeting this criterion, patients must also be post-menopausal for a minimum of 1 year or have a negative pregnancy test if they are of childbearing potential. They must also agree to use an acceptable form of contraception from Screening Visit 1 to the final follow-up visit if they are sexually active. Medically acceptable methods of contraception include hormonal contraception (i.e. estrogen, and/or progesterone or preparations that contain a combination of these hormones), non-hormonal intrauterine device or double barrier"

Answered by AI

Are people still being recruited to participate in this research project?

"This study, which was first announced on September 6th 2019 is not currently looking for participants. The most recent update to the trial was made on July 28th 2022. There are 1150 other trials that are presently enrolling patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Uromune in Treating Recurrent Urinary Tract Infections in Women

Dr. J. Curtis Nickel 2019. "Uromune in Treating Recurrent Urinary Tract Infections in Women". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04096820.

All > Rsv